Duchenne muscular dystrophy awaits gene therapy

Solid’s gene therapy disappoints in the clinic, but other gene therapies and exon-skipping agents continue their march, with CRISPR on the way.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dan Jones.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jones, D. Duchenne muscular dystrophy awaits gene therapy. Nat Biotechnol 37, 335–337 (2019). https://doi.org/10.1038/s41587-019-0103-5

Download citation

Further reading